MSCs alleviate experimental colitis by modulating macrophage immunometabolism, and Rg1 pretreatment further enhances this therapeutic potential. This effect may involve exosomal miRNAs that inhibit macrophage glycolysis by suppressing the RAS pathway, one of which is predicted to be miR-574-3p. These results suggest a possible metabolic mechanism underlying MSC-based immunotherapy for ulcerative colitis.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: